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Eastern EuropeObjective. Eastern European countries are contemplating to introduce the high-risk Human Papillomavirus
(HPV)-test as the primary screening test for their cervical cancer screening programme, but its optimal protocol
is yet unknown. The aimof this studywas to compare the costs, effects and cost-effectiveness of different primary
HPV-screening protocols in Eastern Europe, using Slovenia as an example and with respect of local preferences
for screening.
Methods.We evaluated 968 HPV-screening protocols, which varied by screening ages, triage tests (i.e. cytol-
ogy, repeat HPV and/or genotyping) and strategy for women under 35 years old, using the microsimulation
model MISCAN-Cervix.
Results. Within the subset of strategies that would be acceptable for Slovenian women, the optimal HPV-
screening protocol is to start with two cytology tests at age 25 and 28 and switch to 5-yearly HPV screening
from age 30 to 65. When also other protocols were considered, the optimal screening strategy would be 5-
yearly HPV screening from age 30 to 65 only, improving the cost-effectiveness with 5%. Adding genotyping in
the triage algorithm consistently improved cost-effectiveness. Sensitivity analyses showed the robustness of
the results for other situations in Eastern Europe.
Conclusions. Despite differences in cervical cancer epidemiology between Eastern andWestern European re-
gionswhere HPV screeningwas evaluated, the optimal screening protocol was found to be very similar. Further-
more, strategies that were considered socially acceptable to the population were found to be almost as cost-
effective as less acceptable strategies and can therefore be considered a viable alternative to prevent opportunis-
tic screening.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
TheWorld Health Organization (WHO)Director-Generalmade a call
for action to all countries to eliminate cervical cancer (CC) as a public
health problem by reducing the CC age-standardized incidence rate
(ASIR) to less than 4 per 100,000women. Although ASIRs have been de-
clining inmost regions in theworld, Eastern Europe is one of the excep-
tions with an ASIR of 16.0 in 2018 [1]. To reach the WHO goal,en).
nc. This is an open access article undvaccination against high-risk human papilloma virus (HPV) is essential.
Furthermore, it will takemultiple decades until themajority of the pop-
ulation is protected by the vaccine as only youngwomen are being vac-
cinated. To reach theWHO goal on a shorter term, an optimal screening
programme is required, especially for unvaccinated cohorts [2].
Screening for CC using the HPV-test as the primary test has
shown to be more effective and cost-effective than cytology screen-
ing in several modelling studies [3,4]. Multiple trials [5–7] have con-
firmed this increased effectiveness and since 2017, countries across
the world have started to implement nationwide primary HPV-
screening programmes [8].er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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duce the HPV-test as their primary test for CC screening programmes
as well. However, what the optimal screening protocol for a country
is, depends on many factors. These factors include HPV-prevalence, CC
incidence and mortality, as well as screening test characteristics, costs
for screening, diagnosis and treatment. Also, a new protocol must be
clinically, socially and ethically acceptable to the target population,
health professionals and society [9,10]. If not, users and suppliers are
less likely to adhere to the protocol and the unwanted screening behav-
iour in terms of less screening, overuse of screening or use of not-
recommended screening modalities can alter the predicted benefits to
hams ratio including cost-effectiveness of organized screening [11].
As these factors are likely to be different between regions, previously
conducted studies on the cost-effectiveness of primary HPV-screening
in Western Europe might not be applicable to Eastern Europe.
Therefore, this study aims to compare the costs, effects and cost-
effectiveness of 1) different acceptable primaryHPV screening protocols
in Eastern Europe and 2) all potential primary HPV-screening protocols
in Eastern Europe. We will use Slovenia as an example because of the
high quality data available in Slovenia as it is one among the rare coun-
tries in this region where organized CC screening is implemented and
monitored. Slovenian women are currently invited for screening every
three years from age 20 [12], so deviating too far from that would not
be acceptable for themand could therefore lead to opportunistic screen-
ingwhichwould deteriorate the balance between harms and benefits of
screening [11].
Our analyseswill focus on unvaccinated cohorts only. These analyses
will aid policymakers in Eastern European countries to select a primary
HPV-screening protocol that has the right balance between harms, ben-
efits and costs of CC screening.
This modelling study is a part of the EU-TOPIA (Towards improved
screening for breast, cervical and colorectal cancer in all of Europe) pro-
ject inwhichmodelling is used to quantify the harms, benefits and costs
of organized screening strategies for breast, colorectal and cervical can-
cer in Europe.2. Methods
To analyse the cost-effectiveness of primary HPV-screening proto-
cols, we used the previously publishedmicrosimulation screening anal-
ysis (MISCAN-Cervix) model [13]. In this microsimulation model, a
population of women is simulated individually including their naturalFig. 1. Schematic representation of MISCAN-Cervix. Women are simulated individually and fol
which may or may not progress sequentially into a pre-invasive CIN grade 1, CIN2, CIN3 and
negative CIN lesions may or may not progress sequentially to CIN2 and CIN3 but will never
positive, depending on the type of test and the progression of the disease at that moment of tim
1. Population characteristicswith regards to age distribution, life expectancy, hysterectomy rate
specific probability of CC being clinically detected because of symptoms; 4. Stage- and age-spec
risk human papillomavirus; CIN, cervical intraepithelial neoplasia; CC, cervical cancer.
119history of CC. Women are at risk for acquiring an HPV infection, which
may or may not progress to various grades of cervical intraepithelial
neoplasia and eventually to CC (Fig. 1). Then, a screening protocol can
be applied to this population to quantify the harms, benefits and costs
of that screening protocol.
2.1. Model development
To represent Eastern Europe best, we adapted the existing model to
Slovenia because of the high quality data available in that Eastern
European country. The effects of potential differences with other
European countries will be quantified in sensitivity analyses [3].
First, the natural history of CC was recalibrated to Slovenian data by
simulating the Slovenian female population between2006 and 2015. All
adjusted model parts are indicated in bold in Fig. 1. Population charac-
teristics such as life expectancy, and probabilities of having a hysterec-
tomy were adapted to the Slovenian population in that time period
and the screening participation was informed by data from National
Cervical Cancer Screening Programme ZORA (‘Zgodnje Odkrivanje
predRAkavih sprememb materničnega vratu’, which means ‘Early de-
tection of precancerous changes of the cervix’) [12]. TheHPV prevalence
was calibrated to positivity rates from Učakar et al. in 2013 [14]. The
age-specific and stage-specific CC incidence was calibrated to data
from the Cancer Registry of Slovenia as well as the age-specific and
stage-specific CC survival probabilities [15]. Test characteristics of cytol-
ogy were calibrated using detection rates during the first years of ZORA
[12]. The fit of the model predictions with the observed data is pre-
sented in Appendix Figs. S1-S3.
Second, the characteristics of the population were adapted so that it
would represent the unvaccinated Slovenian female population be-
tween 23 and 65 years old on 1 January 2020. These characteristics in-
clude age distribution, remaining life expectancy, hysterectomy
probabilities and screening history as described in the appendix. Youn-
ger age cohorts were not evaluated because they were offered HPV vac-
cination and therefore are at lower risk for CC.
2.2. Base case assumptions on screening behaviour and test characteristics
We assumed that attendance rates in primary screening will stay
stable over time regardless of the screening protocol andwould be sim-
ilar to the current attendance rates in Slovenia. This means that about
10% of the population never attends screening and that the remaininglowed up until death. Each women is at risk for acquiring one or multiple HPV-infections,
CC. These progression probabilities are dependent on age and on HPV-genotype. HPV-
progress to cancer. When screening is performed, the test will have a probability to be
e. The parts indicated in bold were adjusted during calibration to the Slovenian situation:
s and screening behaviour; 2. Age-specific hazard rates of acquiring anHPV infection; 3. Age
ific survival of CC; 5. Sensitivity of cytology (was varied in a sensitivity analysis). HPV, high-
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average participation in the country is 75% per screening round [12]. Ad-
herence to repeat testing and colposcopy referral was assumed to be
90%, as is currently the case in Slovenia (Table 1).
As the sensitivity and specificity of cytology in Slovenia have
much improved in the last decade [12,15], using the test characteris-
tics from the period over which the model was calibrated (2006–2015)
would not be representative for what can be expected for the future.
Therefore, we applied the sensitivity and specificity of cytology in the
Netherlands [13].
2.3. Screening protocols
We simulated 968 unique scenarios in which all women were in-
vited to primary HPV-screening. The screening protocols in those sce-
narios differed on five domains (Table 1). First, the starting age of
screening could be 25, 27 or 30. Because of the high HPV prevalence in
youngwomen, screening under age 30would always startwith primary
cytology screening. Women with a high grade cytology result are re-
ferred to colposcopy, while women with a low grade positive cytology
result are invited for a repeat cytology test. Second, the switching age
fromprimary cytology screening to primary HPV-screening could either
be 30, which is directly in protocols where the starting age is 30, or 35.
Third, the maximum age of the last screening round could either be 55,
60, 65 or 70. Fourth, the screening interval could be either 3, 4, 5, 6, 7, 8
or 10 years. Also, protocols were simulated that started with 5-yearly
screening from age 30 and switched to a 10-year interval at age 45,
50, 55 or 60. All protocols starting with cytology screening were evalu-
ated with both a 3-year and a 5-year interval between the cytology
tests. Fifth, the triage strategy after a positive primary HPV-test couldTable 1
Base case assumptions on screening behaviour, screening scenarios, costs and
Variable
Screening participation
Adherence to repeat testing
Adherence to colposcopy referral
Starting agesb,c
Switching ages to primary HPV screening
Maximum screening ages
Screening intervals primary HPV screening(years)c
Screening intervals primary cytology before switching age (years)
Variable Disutility (%)4 Duration (months)4 Co
€ (
Screening
Primary cytology test 0.006 0.5 71
Primary HPV-test 0.006 0.5 57
Reflex cytology after HPV-test 0 0 25
Repeat cytology test 0.006 12 53
Repeat HPV-test 0.006 12 39
Diagnosis and treatment
No CIN detected 0.005 6 22
CIN1 0.03 6 69
CIN2 0.07 12 10
CIN3 0.07 12 12
FIGO1A 0.062 60 39
FIGO1B 0.28 60 94
FIGO2+ clinically detected 0.28 60 86
FIGO2+ screen detected 0.28 60 92
Terminal care 0.712 1 21
HPV, high-risk human papillomavirus; CIN, cervical intraepithelial neoplasia; F
a Distributed over 90% of the population. The remaining 10% of the populati
b Because of the high HPV prevalence in young ages, cytology was always u
c Values outside brackets are considered socially acceptable to the Slovenian
d Both strategies using a screening interval of 10 years for all screening ages a
and switching to a 10-year interval at age 45,50,55 or 60 were simulated.
e Costs for screening include the test kit, laboratory costs, fees for smear tak
120either use genotyping complementary to the reflex cytology test or
not and women who are not directly referred could be followed up by
either a repeat cytology test or a repeat HPV-test (Appendix Fig. S4).
Screening programs should be socially and ethically acceptable to
screening participants [9,10]. Therefore we categorized each protocol
as either currently acceptable or not (Table 1). Based on expert opinion,
we assumed a starting age of 25, a maximum interval for cytology
screening of 3 years and a maximum interval for HPV-testing of
6 years to be acceptable for unvaccinated Slovenian women as it
would not deviate too far from current practice.
2.4. Cost-effectiveness analyses
For each scenario, we simulated 10 million unvaccinated women
alive at 1 January 2020 and followed them up until death of CC or of
other causes. When all simulations were completed, we counted for
each scenario several key outcomes. These outcomes include the num-
ber of screening tests, repeat tests, referrals to colposcopy, CIN2+ de-
tection by screening, CC incidence, CC mortality and lifeyears gained
compared to the scenario in which screening would be stopped. These
outcomes were then multiplied with the corresponding costs and/or
disutility loss if applicable to obtain the total costs and the quality ad-
justed lifeyears (QALYs) gained (Table 1) [4,16,17]. The costs are pre-
sented in euros (€) and are indexed to 1 January 2020. The costs of
screening tests include costs for testkits, smeartaker fees, laboraty
costs and costs for organization of the screening programme. Because
the costs of the screening HPV-test when implemented on a national
level in Slovenia is yet unknown, we assumed for the base-case analysis
that the price of the HPV-test would be the same as in the Netherlands,
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on is assumed never to participate in screening.
sed as the primary screening test for women under age 30.
population.
swell as strategies startingwith a screening interval of 5 years from age 30
ers and costs for organization of the screening programme.
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plied disutility set [3,4]. An annual discounting rate of 3% was used for
both costs and effects, as stated in the recommendations for cost-
effectiveness analyses by Sanders and colleagues in 2016 [18].
For calculating the incremental cost-effectiveness ratio (ICER), we
used a two-step approach: In the first step, we only included protocols
that would be considered as currently acceptable for Slovenian
women (Table 1) and calculated the ICER for those strategies. As a sec-
ond step, we added the remaining protocols (Table 1) to evaluate to
what extend the cost-effectiveness can be improved if those restrictions
would be overcome.
An ICER is calculated by first removing all considered strategies that
are more costly and less effective than an alternative strategy or a com-
bination of alternative strategies as they are not efficient. This remaining
set of strategies form the efficient frontier. Next, each strategy is com-
pared to the previous most effective strategy by dividing the extra
costs by the extra QALYs gained, resulting in the ICER.
In general, protocols with an ICER below the gross domestic product
(GDP) per capita are considered very cost-effectivewhile protocolswith
an ICER above three times the GDP per capita are generally no longer
considered cost-effective [19]. To select the optimal screening protocol
in each of the two steps, we applied a willingness to pay (WTP)Fig. 2a. Costs and effects of the screening protocols per 100,000 women simulated and followe
scenario where screening would be stopped, as well as the extra costs that screening would in
121threshold of €50,000 per QALY gained. This threshold is frequently
used in international literature [20,21] and is 1.4 times the GDP per
capita in Slovenia [22], which is at the conservative end of the 1–3
GDP per capita range. However, because the ICERs of all strategies on
the efficient frontiers will be presented, countries can apply their own
WTP threshold. We defined the optimal screening protocol as the
screening protocol on the efficient frontier with the highest number of
QALYs gained with an ICER below the WTP threshold.
2.5. Sensitivity analyses
We performed several univariate sensitivity analyses to analyse the
robustness of our results and because some of those sensitivity analyses
might bemore representative for specific other Eastern European coun-
tries. First, we applied a lower sensitivity of cytology to detect a cervical
intraepithelial neoplasia grade 3 or cervical cancer (CIN3+). Because
screening programs in some Eastern European countries have not
been running for a long time or screening has no extensive quality as-
surance and control, the quality of cytology might not be optimal yet.
We applied a sensitivity of 53% for cytology being atypical squamous
cells of undetermined significance (ASC-US)+ in women with CIN3+,
as this was the lowest reported sensitivity available in situationsd until death. For each protocol it is displayed howmany QALYs are gained compared to a
cur. QALY, quality adjusted life year.
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tive set of published disutilities because these are dependent on the
preferences of women regarding screening, diagnosis and treatment
[24]. Third, we increased the price of the HPV-test with €42.31 to
show the cost-effectiveness of all protocols in case the current price dif-
ference between the HPV-test and cytology in Slovenia could not be re-
duced. Fourth, we varied screening participation by lowering the
attendance with 10 and 25 percentage points to 65% and 50% respec-
tively and by increasing the attendance with 10 percentage points to
85% because attendance to primary screening might be different be-
tween countries and might be affected by the implemented screening
protocol. Lastly, we simulated the scenarios with perfect screening at-
tendance and follow-up adherence to find what the optimal screening
protocol would be for women who perfectly adhere to the guidelines.Fig. 2b. Costs and effects per 100,000women simulated and followed until death of the screenin
simulated protocols. The efficient frontiers are indicated by the solid lines and do not contain st
alternative strategies. For each strategy on the frontier it is displayed howmanyQALYs are gaine
screening would incur. The numbers next to the protocols refer to the strategy numbers as list
frontier indicated by a red square represent the optimal strategies for a willingness to pay thres
1223. Results
Fig. 2a shows the discounted total net costs and total QALYs gained
of all 968 simulated protocols per 100,000 unvaccinated Slovenian
women alive on 1 January 2020 and followed lifelong.
The protocols with the largest screening intervals, and therefore the
least screening rounds, are the cheapest protocols but also gain the least
QALYs and are therefore on the bottom left of the spectrum. The oppo-
site is true for protocols with the shortest screening intervals.
Cost efficient screening protocols gain the maximum number of
QALYs for a given amount of costs. Those protocols lie on the efficient
frontier (Fig. 2b). The black dots represent seven protocols that are on
the efficient frontier of protocols that are considered acceptable for
Slovenian women. The grey dots represent the thirteen protocols ong protocols on the efficient frontier of acceptable protocols or on the efficient frontier of all
rategies that gain less health for more costs than alternative strategies or a combination of
d compared to a scenariowhere screeningwould be stopped, aswell as the extra costs that
ed in Tables 2a and 2b which also include the ICER of each strategy. The strategies on each
hold of €50,000. QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio.
Table 2a
Primary HPV-screening protocols on the efficiency frontier of acceptable protocols (see Fig. 2b). Bold indicates the optimal protocol under the cost-effectiveness
threshold of €50.000 per QALY gained.
Protocol number Age range Screening interval Number of Screening rounds QALYs gaineda,b Extra costsa,b
(x million €)




































16 1180 23.3 486,371
QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio.
a Per 100,000 women simulated lifetime, compared to a no screening scenario.
b Discounted annually by 3%.
c This age range is screened with the primary cytology strategy.
E.E.L. Jansen, U. Ivanuš, T. Jerman et al. Gynecologic Oncology 160 (2021) 118–127the efficient frontier of all simulated protocols. The frontiers deviate
from each other at the left of the graph where the cheapest protocols
are located and almost merge again halfway from where they stay
close to each other towards the right of the graph, but they never cross.
The characteristics of the protocols on both of the efficient frontiers
are described in Table 2a and Table 2b, including their corresponding
discounted net cost, QALYs gained and ICER. All strategies on the fron-
tier apply genotyping as a direct triage strategy and use the HPV-test
as the repeat test (Appendix Fig. S4, strategy 4).
Based on a WTP threshold of €50,000 per QALY gained, the optimal
screening protocol within the set of acceptable strategies would be to
start 3-yearly cytology screening from age 25 to 28 and switch to 5-
yearly HPV-screening from age 30 to 65, leading to a total of 10 lifetime
screens (ICER within acceptable strategies: €42,864 per QALY gained,
Table 2a). When considering all simulated protocols, the optimalTable 2b
Primary HPV-screening protocols on the efficiency frontier of all simulated pr
effectiveness threshold of €50.000 per QALY gained.
Protocol number Age range Screening interval Number of Scree
8 30–50 10 3
9 30–60 10 4











13 30–66 6 7























QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio.
a Per 100,000 women simulated lifetime, compared to a no screening scenari
b Discounted annually by 3%.
c This age (range) is screened with the primary cytology protocol.
123screening protocol is 5-yearly HPV-screening from age 30 to 65 (ICER:
€45,406 per QALY gained, Table 2b).
If a WTP threshold of three times the GDP per capita in Slovenia
would be applied (€106,853), the optimal screening protocol would be-
come 5-yearly HPV-screening from age 35 to 70, with cytology screen-
ing at ages 27 and 32.Within the acceptable screening protocols, also 5-
yearly HPV-screening from age 35 to 70 would become the optimal
strategy, but with 3-yearly cytology screening from age 25 to 34.
For all protocols on both frontiers, the undiscountedmain results as
well as other important indicators are presented in Table 3a and
Table 3b. Both tables show thatwith increasing screening intensity, the
number of primary screens increases (70,482–507,628) as well as the
number of repeat tests (4459–22,056), colposcopies (2969–10,454)
and CIN2+ lesions detected by screening (1542–3431). The only excep-
tion is the number of referrals for colposcopy of strategy 6. Furthermore,otocols (see Fig. 2b). Bold indicates the optimal scenario under the cost-
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well as the cancer mortality (237–112) go down and the number of
lifeyears gained (2000–3849) and QALYs gained (2078–3872) go up.
The total costs go up as well (€15.4 million – €42.1 million) because of
the increasing costs of screening. This while the costs of diagnosis and
treatment remain more or less constant because although the costs of
cancer diagnosis and treatment decrease, the costs of CIN diagnosis
and treatment increase.
3.1. Sensitivity analyses
The results of the sensitivity analyses are presented in Table 4. It
shows for all alternative screening assumptions what the optimal HPV
screening protocol would be when considering all simulated screening
protocols and applying a WTP threshold of €50,000. The optimal
starting age of screening remains 30 for all sensitivity analyses although
in case of the alternative disutility assumptions or higher costs for the
HPV-test, that first screening would be a cytology test instead of an
HPV-test. The end age of screening varies between 63 and 70 across
the sensitivity analyses and the optimal screening interval increases
from 4 years in case of 25% lower attendance to primary screening up
to 8 years in case of perfect screening attendance and adherence to
follow-up. The protocols to the direct left and right of the optimal
screening protocol on the efficient frontier are also presented in
Table 4. These protocols represent the optimal screening strategy if
screening needs to be either less costly or more effective. All screening
protocols on the efficient frontier of the sensitivity analyses are pre-
sented in Appendix Fig. S5 and Tables S1–S8 including the associated
costs, QALYs gained and ICER.
4. Discussion
Our modelling analyses show that for a WTP threshold of €50,000,
the optimal HPV screening protocol for Eastern Europe would be 5-
yearly screening from age 30 to 65 where HPV-positive women would
be triaged depending on the HPV genotype and cytology result. If this
does not warrant a direct referral, repeat testing should be performed
with an HPV-test. If it would not be acceptable for the population toTable 3a


























































507,628 22,056 10,454 3431 217
CC, cervical cancer; CIN, cervical intraepithelial neoplasm; QALY, quality-adjusted life year; CE
a compared to a no screening scenario.
b women are only counted once per attended repeat test, if this repeat test would incur a refle
repeat tests as this does not cause extra harms to women.
c This age (range) is screened with the primary cytology protocol.
124start screening later than at age 25 and if the screening interval of pri-
mary cytology should not exceed 3 years, a cytology screen at age 25
and 28 can be added to that HPV screening protocol, although this will
incur 5% extra costs without an additional gain in QALYs.
It is advised to add an extra screening round at age 70 in Eastern
European countrieswhere either the sensitivity of cytology or the atten-
dance in primary screening is lower than assumed for Slovenia. If the at-
tendance in primary screening would become 25% lower, the screening
interval would be lowered to 4 years as well. If either the screening at-
tendance or the costs of the HPV-test would be higher, the screening
protocol can become less intensive than in the base case.
Furthermore, our analyses show that the optimal screening protocol
is dependent on preferences of the population, reflected by the disutility
weights of screening, diagnosis and treatment aswell as acceptability of
target ages for screening and screening intervals. Both of these prefer-
ences are dependent on the culture and values ofwomenwithin a coun-
try and should be considered when selecting the optimal screening
protocol. The effect of applying different disutility assumptions on the
optimal screening protocol has been demonstrated in a previous study
[24]. Our study shows that the efficient frontier of acceptable protocols
is very close to the efficient frontier of all simulated protocols. This im-
plies that the loss in cost-effectiveness by restricting to protocols that
are acceptable is relatively small and should therefore be considered.
Lastly, theWTP threshold is an important factor in selecting the opti-
mal screeningprotocol. This threshold is country specific anddependent
on the severity of the disease, other available interventions and the
maximum budget that can be spent on health [19].4.1. Strengths and limitations
This study has some noteworthy strengths and limitations. One
strength is that we evaluated many different screening protocols, in-
cluding those with longer screening intervals. By including sufficient
comparator strategies, especially around the WTP threshold, we
avoided an underestimation of the ICER of the optimal strategy [25]. A
second strength is that we evaluated those strategies with a




















326 – – – 12.0 12.0 –
204 2664 2736 8.8 11.1 19.9 2889
168 3093 3206 11.9 10.4 22.3 3211
141 3338 3473 15.4 9.9 25.3 3816
136 3485 3601 17.3 10.1 27.4 4266
122 3594 3707 20.9 9.9 30.8 5072
121 3637 3744 22.1 9.9 32.0 5332
112 3849 3872 31.2 10.9 42.1 7783
, cost-effectiveness.
x test, the costs of this reflex test are added to the screening costs, but not to the number of
Table 3b








































0 – – – – – – 567 326 – – – 12.0 12.0 –
8 30–50 10 70,482 4459 2969 1542 429 237 2000 2078 4.4 11.0 15.4 1647
9 30–60 10 122,369 6341 3918 1851 364 188 2583 2725 7.5 10.0 17.5 2009










234,372 10,854 5985 2553 289 144 3297 3444 14.4 9.7 24.1 3512
13 30–66 6 242,428 11,312 6356 2602 285 141 3323 3467 14.8 9.8 24.6 3619





332,896 14,232 7393 2839 260 123 3552 3678 20.3 9.7 30.0 4901










345,574 15,153 7629 2912 254 121 3605 3722 21.3 9.8 31.1 5123





497,004 21,200 10,271 3386 218 112 3833 3865 30.4 10.8 41.3 7564
CC, cervical cancer; CIN, cervical intraepithelial neoplasm; QALY, quality-adjusted life year; CE, cost-effectiveness.
a compared to a no screening scenario.
b women are only counted once per attended repeat test, if this repeat test would incur a reflex test, the costs of this reflex test are added to the screening costs, but not to the number of
repeat tests as this does not cause extra harms to women.
c This age (range) is screened with the primary cytology protocol.
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never done before.
A third strength is that we did not only take cost-effectiveness into
account, but also considered which protocols would be acceptable to a
population that is currently intensively screened. By doing this, we pro-
vide policymakers with added information on how much the cost-
effectiveness would deteriorate if they would adhere to specific prefer-
ences of the population. To the best of the authors' knowledge, this is
the first study to present both the ICERs of an extensive spectrum of
CC screening protocols aswell as ICERs of a selection of acceptable strat-
egies. A limitation of our study is that the assumptions on costs could
not directly be informed by observed costs in Eastern Europe, partly be-
cause there is no primary HPV-screening programme in place yet. The
costs of an HPV-test can affect the conclusions substantially as shown
in the sensitivity analyses. In case the current price difference betweenTable 4
Sensitivity analyses. The Optimal target age range and screening interval are presented for eac
protocols are presented which are on the efficiency frontier and are either one step less costly
Scenario Optimal protocol (age range and





Base case – – 30–65 5
Lower sensitivity cytology – – 30–70 5
Alternative disutility assumptions 30 – 35–65 6
Higher costs of HPV-test 30 – 35–63 7
Attendance primary screening −10% – – 30–70 5
Attendance primary screening +10% – – 30–66 6
Attendance primary screening −25% – – 30–70 4
Perfect attendance and adherence to follow-up – – 30–70 8
WTP, willingness-to-pay; cyt., cytology; Int., interval; HPV, human papillomavirus.
a This age (range) is screened with the primary cytology protocol.
125cytology and the HPV-test would be maintained, the optimal screening
strategy would contain only 6 screening rounds instead of 8 under base
case assumptions. Eastern European countries should therefore care-
fully check whether the cost assumptions would be valid for them as
well before utilizing the results. A second limitation of the study is
that opportunistic screening was not taken into account. The costs and
effects of all protocols were compared to a no screening scenario. How-
ever, in absence of organized screening there is often opportunistic
screening present, which does not promote equity, causes more harms
and is not monitored for quality assurance, all making screening less
cost-effective [11]. If organized screening would replace the inefficient
opportunistic screening activities, the simulated screening protocols
would be even more cost-effective than indicated in this study. Lastly,
a stable HPV prevalence was assumed over time. If the HPV prevalence
would increase, the risk for CC could increase aswell and amore intenseh of the alternative screening assumptions assuming a WTP threshold of €50,000. Also the
and less effective, or more costly and more effective.
Less costly, less effective (age range
and screening interval by test type)
More costly, more effective (age range









– – 30–66 6 27–32 5 35–70 5
– – 30–65 5 – – 30–70 4
30 – 35–63 7 30 – 35–65 5
– – 30–63 8 30 – 35–65 6





– – 30–70 5
30 – 35–67 4 27–33 3 35–68 3
30 – 35–67 8 30 – 35–70 7
E.E.L. Jansen, U. Ivanuš, T. Jerman et al. Gynecologic Oncology 160 (2021) 118–127screening protocol might become optimal. However, if only the HPV
prevalence increases and the CC risk not, the optimal screening intensity
will not change that much.
Although it was shown that the conclusions might be dependent on
specific model assumptions, it is clear from our results that when pri-
mary HPV-screening would be implemented, the screening interval
should be at least 5 years. Although we assumed this would be an ac-
ceptable interval for women in Eastern Europe, some of them might
be used to shorter screening intervals in current programmes. Shorter
screening intervals with HPV screening will gain only few extra QALYs
while incurring considerably more costs. Therefore, it is especially im-
portant to minimize opportunistic screening when implementing pri-
mary HPV screening. This might be more challenging if screening
intervals are longer.
Ourfindings are in linewithanalysesperformed inother regions. Van
Rosmalen et al. showed that for the Netherlands 6-yearly primary HPV-
screening from age 30 to 66 would be the optimal protocol applying a
WTP threshold of €50,000 when considering a wide range of protocols
[4]. A study for the setting of New Zealand reported an optimal protocol
of 5-yearly HPV-screening in women aged 25–69, although protocols
with a higher starting age were not considered in this study [26].
Screening vaccinated cohorts of women was outside the scope of
this study. However, these vaccinated women will enter the ages that
are eligible for screening in several Eastern European countries (includ-
ing Slovenia) very soon. These vaccinated women are at lower risk for
CC and because of that will require less intensive screening [27]. There-
fore separate analyses should be performed on optimizing screening in
vaccinated cohorts in Eastern Europe.
5. Conclusion
Although Eastern Europe differs fromWestern Europe on many fac-
tors that influence the cost-effectiveness of screening programmes, we
showed that the optimal HPV screening programme is similar to that
of Western Europe. The optimal screening protocol for individual East-
ern European countries depends on preferences of women, the WTP
threshold and screening attendance. However, it can be concluded
that if HPV screening is implemented, the screening interval should be
at least five years and should be continued until an age between 60
and 70.
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